AG真人国际-(china)官方网站

日本語
Research and Development
Strong, Innovation-driven R&D Capabilities
 
R&D Field
Cancer Types Covered by the R&D Pipeline
 
  • Lung
    Cancer
  • Breast
    Cancer
  • Gastric
    Cancer
  • Gynecological
    Cancer
  • Hematologic
    Malignancies
Rich and Balanced Pipeline
  • 1 product – Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug has been conditionally approved by NMPA that Haihe owns its global intellectual property rights.
  • 10+ Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
  • Multiple potential best-in-class compounds are expected to be used in monotherapy or combination to treat major indications
Approved Products
R&D Pipeline

Pipeline
Indication 

NSCLC with METex14 skipping mutation

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

     
  •  

    NDA

     
  •  

    Launched

     

NSCLC with METex14 skipping mutation(Confirmatory study)

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

     
  •  

    NDA

Immuno and chemo failure &MET overexpression NSCLC

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

     
  •  

    NDA

Indication

Advanced Gastric Cancer

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

     
  •  

    NDA

     
  •  

HER2-negative Breast Cancer

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

     
  •  

    NDA

  •  

Indication

Advanced ES and other advanced solid tumors

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

  •  

    NDA

Follicular Lymphoma

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

  •  

    NDA

PTCL

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Indication

Ovarian , Oviduct or Primary peritoneal clear cell carcinoma

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

  •  

    NDA

Breast Cancer(Combined endocrine therapy)

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Vascular malformations

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Advanced Solid Tumor

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Indication 

Malignant hematoma, Solid Tumor

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Indication 

Malignant hematoma, Solid Tumor

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Indication 

Solid Tumor

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Indication 

Solid Tumor

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Indication 

Solid Tumor

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Indication 

Solid Tumor

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

  •  

    Phase III

  •  

    NDA

Indication

Diabetic Foot Ulcer

  • Stage

    Preclinical

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Phase III

     
  •  

    NDA

     
  •  

 

Follow Us
©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备12016151号-1
友情链接: